Peptide Inhibitors

* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).

Online Inquiry

CAT# Product Name M.W Molecular Formula Inquiry
HB00012 Fitc-VAD-FMK 722.7414 C35H35FN4O10S Inquiry
HB00013 Biotin-VAD-FMK 559.6544 C24H38FN5O7S Inquiry
HB00014 Boc-D-FMK 263.2654 C11H18FNO5 Inquiry
HB00015 Z-DEVD-FMK 668.6724 C30H41FN4O12 Inquiry
HB00016 Fitc-DEVD-FMK 923.9194 C43H46FN5O15S Inquiry
HB00017 Biotin-DEVD-FMK 760.8324 C32H49FN6O12S Inquiry
HB00018 Z-IETD-FMK 654.6894 C30H43FN4O11 Inquiry
HB00019 Fitc-IETD-FMK 907.9644 C44H50FN5O13S Inquiry
HB00020 Biotin-IETD-FMK 746.8494 C32H51FN6O11S Inquiry
HB00021 Z-FF-FMK 462.5214 C27H27FN2O4 Inquiry
HB00022 Fitc-FF-FMK 715.7964 C41H34FN3O6S Inquiry
HB00023 Biotin-FF-FMK 554.6814 C29H35FN4O4S Inquiry
HB00024 Z-ASTD-FMK 556.5444 C24H33FN4O10 Inquiry
HB00025 Fitc-ASTD-FMK 809.8194 C38H40FN5O12S Inquiry
HB00026 Biotin-ASTD-FMK 648.7044 C26H41FN6O10S Inquiry
HB00027 Z-ATAD-FMK 540.5454 C24H33FN4O9 Inquiry
HB00028 Fitc-ATAD-FMK 793.8204 C38H40FN5O11S Inquiry
HB00029 Biotin-ATAD-FMK 632.7054 C26H41FN6O9S Inquiry
HB00030 Z-FA-FMK 386.4234 C21H23FN2O4 Inquiry
HB00031 Fitc-FA-FMK 639.6984 C35H30FN3O6S Inquiry

Peptide inhibitors have the advantages of high affinity and specificity, low production cost, etc., and have attracted the attention of researchers.

Introduction of peptide inhibitors of PD-1/PD-L1 signaling pathway

Phage display technology is an efficient biological panning method that uses targets to screen high-affinity peptides and antibodies from libraries. Kotraiah et al. reported that four high-affinity phage clones were screened using recombinant human PD-1 protein, and the peptide sequence displayed on the surface of the phage was chemically synthesized to obtain PD-1 peptide. In vitro experiments proved that PD-1 peptide can bind to human PD-1 receptor and block PD-L1 binding; molecular simulation results showed that PD-1 peptide can bind to specific sites of PD-1 to exert biological activity. In vivo experiments proved that, PD-1 peptide had anti-melanoma metastasis ability similar to PD-1 mAb, increased the survival rate of lethal sepsis in mice, and can also be used as an immune adjuvant to improve the protective efficacy of preventive malaria vaccines. In addition, computer-aided peptide inhibitor design and peptide or peptidomimetic inhibitors designed based on PD1/PD-L1 functional fragments are also in progress.

Introduction to CCR5 and HIV gp120 peptide inhibitors

The role of CCR5 and gp120 has made it an attractive target for anti-HIV-1 drug research. Some polypeptides derived from the extracellular region of CCR5 and some antibodies can selectively interact with the surface glycoprotein of the virus and have the effect of inhibiting the fusion of the virus with cells. Yu Yong et al. designed a series of peptide analogues based on the crystal structure of a monoclonal antibody 17b that directly interacts with gp120, and selected a peptide P20 from them. By testing the ability of the polypeptide to inhibit virus entry, it was found that P20 has a significant ability to inhibit the entry of R5 HIV-1 into human peripheral blood mononuclear cells (PBMC), and had no significant effect on the entry of R4 HIV-1.

Introduction to L-JNK peptide inhibitor

L-JNK Peptide Inhibitor competitively blocks the interaction between JNK and c-Jun, thereby inhibiting the signaling events downstream of JNK, like c-Jun, ATF-2 and ELK1 phosphorylation. To convert JIP-1/IB-1 into cell permeable inhibitors of JNK (JNKI1) the minimal 20 amino acids inhibitory sequence of JIP-1/IB1 was covalently linked to the 10 amino acids recognized by TAT transporter. The L-JNKI1 is a potent inhibitor that is specific for JNK and can be used for in vitro applications.

It is worth noting that peptide inhibitors themselves also have disadvantages that need to be improved, such as instability in the body and poor membrane penetration ability. It has been reported in the literature that the combination of configuration transformation and nanotechnology can improve the efficacy of drugs. In addition, polypeptide structure modification, such as introduction of hydrophilic groups, side chain modification, cyclization, etc., can further improve its biological activity and druggability.

References

  1. Kotraiah Vinayaka, Phares Timothy W, Browne Cecille D, et al. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.[J]. Frontiers in Immunology, 2020, 11:264.
  2. Yu Yong et al., Chinese Science Bulletin, 2004, 49(18): 1913-1914
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Customer Support & Price Inquiry

Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!

  Vasoconstrictor substances, such as norepinephrine and epinephrine, have been mingled with local anesthetics to ...

  Eptifibatide acetate is a white or white-off powder, soluble in water and freely soluble in 1% acetic in water, ...

 Zonisamide, sold as brand name Zonegran, is a derivative of 3-(sulfamoylmethyl)-l,2-benzisoxazole. It is a membe ...

 NoxA1ds is derived from a peptide whose structure is based on a short sequence of an essential Nox subunit. It b ...

 Angiotensin Ⅱ is a kind of peptides generally produced by the hydrolysis of the angiotensin Ⅰ under the angioten ...

Quick Inquiry
×
Contact Us

USA

Address:

Tel: |

Email:

Germany

Address:

Copyright © 2024 Creative Peptides. All rights reserved.